Pyoderma gangrenosum - 壊疽性膿皮症
壊疽性膿皮症 (Pyoderma gangrenosum) は、痛みを伴う膿疱や結節が潰瘍となり、徐々に拡大する稀な炎症性皮膚疾患です。壊疽性膿皮症 (pyoderma gangrenosum) は感染性ではありません。治療には、コルチコステロイド、シクロスポリン、または各種モノクローナル抗体が用いられます。あらゆる年齢層に発症する可能性がありますが、特に40代・50代に多く見られます。
☆ AI Dermatology — Free Service
ドイツの2022年Stiftung Warentestの結果では、ModelDermに対する消費者満足度は有料の遠隔医療相談よりもわずかに低いだけでした。
ドイツの2022年Stiftung Warentestの結果では、ModelDermに対する消費者満足度は有料の遠隔医療相談よりもわずかに低いだけでした。
潰瘍性大腸炎の方の脚。
relevance score : -100.0%
ReferencesPyoderma gangrenosum は、赤または紫がかった縁を持ち、痛みを伴う潰瘍を引き起こすまれな皮膚疾患です。炎症性疾患として分類され、好中球性皮膚炎と呼ばれるグループに属します。Pyoderma gangrenosum の原因は複雑で、遺伝的に罹患しやすい人々において、自然免疫と適応免疫の両方に異常が関与しています。最近、研究者は毛包が病態の潜在的な起点である可能性に注目しています。
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum は、非常に痛みを伴う潰瘍を引き起こす稀な皮膚疾患です。その原因は完全には解明されていませんが、特定の免疫細胞の活性化が関与していることが分かっています。治療は依然として容易ではなく、免疫系を抑制したり活性を調整したりするさまざまな薬が用いられます。当院では、創傷の管理や痛みの緩和にも力を入れています。多くの場合、Corticosteroid と Cyclosporine が第一選択となりますが、近年は TNF-α阻害剤などの生物学的療法の研究が増えています。これらの生物学的製剤は、特に他の炎症性疾患を抱える患者において、病気の進行が早い段階で使用されることが増えてきています。
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
